All In Biotech

Drug Trial Radar · NCT03069508

Clemizole HCl for Subjects With Hepatocellular Carcinoma

A Phase IIa, Open Label Pilot Study of Clemizole Hydrochloride Given Orally Thrice a Day, for Subjects With Hepatocellular Carcinoma That Are Either Awaiting Transplantation or Have an Unresectable Lesion

Last checked: Nov 19, 2026Latest source record: Mar 3, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

12

Planned (sponsor's estimate)

Start

Feb 13, 2017

Primary completion

Dec 31, 2017

Study completion Jan 31, 2018

Sponsor

Sponsor type
Industry
First posted
Mar 3, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase IIa open label pilot study of up to six months treatment with clemizole hydrochloride (200 mg vs. 300 mg vs. 400 vs. 500 mg mg) given orally TID to subjects with hepatocellular carcinoma that are either awaiting transplantation or have an unresectable lesion.

Conditions

  • Hepatocellular Carcinoma

Interventions

  • Clemizole HydrochlorideDrug

    Clemizole Hydrochloride will be administered orally for up to 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse eventsTime frame: Number of recorded adverse events at six months
  2. Overall tumor response according to radiologic assessments associated with clemizole HCl.Time frame: Change from baseline up to 24 weeks
  3. AUC Pharmacokinetic (PK) assessment of clemizole hydrochloride (200 mg vs. 300 mg vs. 400 mg vs. 500 mg by mouth)Time frame: 0-pre-dose, post dose: 15 min, 30 min, 60 min, 90 min, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours post oral administration of clemizole HCl for those subjects participating in the PK portion of this trial
  4. Cmax Pharmacokinetic (PK) assessment of clemizole hydrochloride (200 mg vs. 300 mg vs. 400 mg vs. 500 mg by mouth)Time frame: 0-pre-dose, post dose: 15 min, 30 min, 60 min, 90 min, 2 hours, 2.5 hours, 3 hours, 4 hours, 6 hours, 8 hours post oral administration of clemizole HCl for those subjects participating in the PK portion of this trial

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Ankara

    Ankara, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.